Afoxolaner 是一种具有口服活性的，对犬肩蜥的异恶唑啉杀虫剂/杀螨剂。Afoxolaner 作用于昆虫的 γ-氨基丁酸受体 (GABA) 和谷氨酸受体 (glutamate receptors)，抑制 GABA 和谷氨酸调节的氯离子 (chloride ions) 吸收，导致过度的神经元刺激和节肢动物死亡。

英文别名:

4-[5-[3-Chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide

Fluralaner, also known as AH252723, is a systemic insecticide and acaricide that is administered orally. The US Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014. The EU approved the drug in February 2014. Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and l-glutamate-gated chloride channels (GluCls).